CFRA Initiates Warby Parker(WRBY.US) With Buy Rating, Announces Target Price $20
Warby Parker Analyst Ratings
JMP Securities Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $20
JMP Securities Upgrades Warby Parker(WRBY.US) to Buy Rating, Announces Target Price $20
Piper Sandler Maintains Warby Parker(WRBY.US) With Buy Rating, Cuts Target Price to $18
Analysts Offer Insights on Healthcare Companies: Quanterix (QTRX), Doximity (DOCS) and Warby Parker (WRBY)
Loop Capital Markets Reaffirms Their Hold Rating on Warby Parker (WRBY)
JMP Securities Reaffirms Their Hold Rating on Warby Parker (WRBY)
Warby Parker Analyst Ratings
Telsey Advisory Sticks to Its Buy Rating for Warby Parker (WRBY)
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals Ltd. (TLPPF), Warby Parker (WRBY)
Telsey Advisory Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $19
Warby Parker Analyst Ratings
Warby Parker Analyst Ratings
Warby Parker (WRBY) Gets a Hold From Loop Capital Markets
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Warby Parker Analyst Ratings
Telsey Advisory Remains a Buy on Warby Parker (WRBY)
Morgan Stanley Lifts Price Target on Warby Parker to $14 From $13, Keeps Equalweight Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)